Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.
Reshape Lifesciences, Inc. is a medical device company focused on the development of non-surgical weight loss devices for obese or overweight patients. The company offers a range of innovative products, including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation. Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the growing demand for safe and effective options in the market.
News
Rhea-AI Summary
ReShape Lifesciences, Inc. (RSLS) announces an agreement to exercise outstanding warrants with an investor, resulting in the purchase of 5,382,500 shares of common stock and issuance of new unregistered warrants for 10,765,000 shares. The exercise price of the warrants has been reduced to $0.23, and the new warrants will become exercisable six months following issuance. The company will seek stockholder approval for potential further reduction of the exercise price. The gross proceeds from the exercise of the existing warrants was approximately $1.2 million, with the net proceeds intended for commercial growth, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
-
Rhea-AI Summary
ReShape Lifesciences Inc. (Nasdaq: RSLS) reported a 37% reduction in core operating expenses compared to the third quarter of 2022. A cost reduction plan aims to cut operating expenses by over 40% in 2024 compared to 2023. The company also highlighted a recent exclusive licensing agreement, a strengthened patent portfolio, and a successful public offering. The CEO emphasized the impact of GLP-1 adoption on the medical weight loss market and the company's strategic measures to address this, including significant cost cuts and investment in growth drivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
-
Rhea-AI Summary
ReShape Lifesciences Inc. will report its financial results for Q3 2023 on November 8, 2023. The company will also provide a corporate update. A conference call will be held at 5:00 pm ET on November 8, with a live webcast available on the company's website. Participants can access the call by phone and an archived replay will be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
Rhea-AI Summary
ReShape Lifesciences® announces pricing of public offering of 9.1M units at $0.33 each, expecting gross proceeds of $3.0M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.18%
Tags
-
Rhea-AI Summary
ReShape Lifesciences to present company overview at LD Micro's Annual Main Event, highlighting Lap-Band program and ReShapeCare virtual weight-management program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
-
Rhea-AI Summary
ReShape Lifesciences signs exclusive license agreement with Biorad Medysis to distribute Obalon Gastric Balloon System in Indian Subcontinent
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
Rhea-AI Summary
ReShape Lifesciences strengthens patent portfolio for Obalon Balloon System, with one patent granted and two notices of allowance received
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.64%
Tags
-
Rhea-AI Summary
ReShape Lifesciences® receives $331,541 SBIR grant for development of DBSN™ device to treat Type 2 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ReShape Lifesciences Inc. reports financial results for Q2 2023, with a 53% reduction in operating expenses compared to last year. The company made operational improvements and invested in growth drivers. They signed a preferred partner agreement with Hive Medical for lead optimization software. They also submitted a PMA supplement application to the FDA for their next generation Lap-Band® 2.0. Revenue contracted in Q2 2023 compared to the same period last year, but the company expects growth in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
The current stock price of Reshape Lifesciences (RSLS) is $1.12 as of February 21, 2025.
What is the market cap of Reshape Lifesciences (RSLS)?
The market cap of Reshape Lifesciences (RSLS) is approximately 4.1M.
What is Reshape Lifesciences, Inc. focused on?
Reshape Lifesciences, Inc. is a medical device company focused on developing non-surgical weight loss devices for obese or overweight patients.
What are some of the products offered by Reshape Lifesciences?
Reshape Lifesciences offers a range of products including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation.
What is the goal of Reshape Lifesciences?
Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the demand for safe and effective options in the market.
How does Reshape Lifesciences contribute to the medical field?
Reshape Lifesciences contributes to the medical field by offering innovative and advanced technologies to treat obesity and metabolic diseases.
Reshape Lifesciences Inc.
Nasdaq:RSLS
RSLS Rankings
RSLS Stock Data
4.07M
666.88k
5.58%
1.83%
4.94%
Medical Devices
Pharmaceutical Preparations
United States
SAN CLEMENTE